Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics Inc (ACRS)

By Jason Carr

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Aclaris Therapeutics Inc (ACRSResearch Report) today and set a price target of $50. The company’s shares closed yesterday at $5.91, close to its 52-week low of $5.49.

Chen said:

“We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50.”

According to, Chen is a 5-star analyst with an average return of 13.6% and a 41.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.

Aclaris Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $50.

See today’s analyst top recommended stocks >>

Based on Aclaris Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $32.74 million. In comparison, last year the company had a GAAP net loss of $22.93 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address unmet needs in medical and aesthetic dermatology and immunology. It operates thrpough Dermatology Therapeutics and Contract Research segments.